Stop Drug Trials in China: Matas

By Sanders, Carol | Winnipeg Free Press, August 1, 2012 | Go to article overview

Stop Drug Trials in China: Matas


Sanders, Carol, Winnipeg Free Press


City lawyer fears use of executed prisoners' organs

A Winnipeg human rights lawyer is trying to prevent a Canadian drug company from testing its kidney-transplant medication in China where prisoners -- not voluntary donors -- provide most organs.

"I'd like them to stop," said David Matas, who's written to the Edmonton company asking it not to do the drug trial in China, and to the authorities in Canada and the United States asking them not to accept the trial's results.

Edmonton-based Isotechnika Pharma Inc. is about to commence clinical trials of the anti-rejection drug Voclosporin in kidney transplant patients in China with the Chinese company 3SBio.

"China has a system that's neither transparent nor accountable," said Matas. Ethically, anybody involved in these trials has to wonder about the source of transplanted organs, he said.

"The government of China acknowledges, literally, all organs come from prisoners," said Matas, citing quotes by Chinese deputy Minister of Health Huang Jiefu. "In China, more than 90 per cent of transplanted organs are obtained from executed prisoners," the minister reportedly said in 2008.

Matas and Ontario Liberal MP David Kilgour say the bulk of prisoners are locked up for practising Falun Gong, a physical and meditative form of spirituality banned in China.

The head of the Canadian drug company said he knows there are concerns about China but he's certain the trial will be conducted ethically.

"In the transplant world, it has been known for a long time that things can be a little bit iffy when it comes to organ transplant in China," said Isotechnika chairman and CEO Robert Foster in Edmonton.

"One thing we've prided ourselves on being is a really, highly reputable company," he said.

In China, Isotechnika will only test its drug on people who received an organ transplant donated by a living relative, he said, and they will test tissue samples to make sure they're a match.

"We're going to set the bar really high," said Foster. The company is spending $60 million on the trial and doesn't want to throw it away on test results that go "up in smoke," said Foster.

"It doesn't make sense," he said.

But with no accountability or transparency in China, Matas maintains there's no way the Edmonton company or drug-approving authorities can be sure of the source of the organs.

"There is nothing now in place, as far as we can see, that would allow your agency to be satisfied beyond a reasonable doubt that the sourcing of the organs for the clinical trials of Voclosporin is proper," he said in a letter to Health Canada and the U. …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Stop Drug Trials in China: Matas
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.